Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Press Release: New results across pediatric, adult and real-world insomnia settings highlight the expanding clinical evidence for daridorexant at Sleep Europe 2026 Phase 2 results with daridorexant in pediatric insomnia disorder will be presented in a late-breaking "Impactful Clinical Trial" session. These are the first and only investigational data of a dual orexin receptor antagonist in children.
Jun 22, 2025 SOURCE: PR NewsWire Once-weekly medication results in weight loss of up to 22.7% in adults without diabetes and 15.7% in those with type 2 diabetes CHICAGO, June 22, 2025 /PRNewswire/ -- Findings from two studies highlight the potential for CagriSema, a dual agonist that targets both glucose regulation and appetite control, to improve weight loss in patients with and without type 2 diabetes who have overweight or obesity.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
